Cure51

Cure51 is a tech-bio company that identifies and collects clinical and multi-omics data from 'cancer outliers,' individuals who survive more than five years after a diagnosis of a lethal cancer. The company utilizes a computational biology team to analyze these datasets to discover multimodal signatures and robust biological targets. These insights are used to develop precision medicine tools and support oncology drug development programs for pharmaceutical and scientific partners.